• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed

    2/19/21 4:10:16 PM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CBMG alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-36498
    Issuer: Cellular Biomedicine Group, Inc.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 530 University Avenue
    Suite 17
    Palo Alto CALIFORNIA 94301
    Telephone number: 949-212-9772
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Common Stock
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2021-02-19 By O'Neil Blake Senior Specialist
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CBMG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CBMG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CBMG
    SEC Filings

    View All

    SEC Form 15-12G filed

    15-12G - Cellular Biomedicine Group, Inc. (0001378624) (Filer)

    3/3/21 2:40:08 PM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed

    EFFECT - Cellular Biomedicine Group, Inc. (0001378624) (Filer)

    2/26/21 12:15:06 AM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed

    EFFECT - Cellular Biomedicine Group, Inc. (0001378624) (Filer)

    2/26/21 12:15:16 AM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CBMG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Jacky Gang Ji

    4 - Cellular Biomedicine Group, Inc. (0001378624) (Issuer)

    2/19/21 3:13:16 PM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Alan Kwok Chun Au

    4 - Cellular Biomedicine Group, Inc. (0001378624) (Issuer)

    2/19/21 3:13:22 PM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4: Yihong Yao disposed to the issuer $0 worth of Common Stock (18,900 units at $0.00) and was granted 54,000 units of Common Stock, decreasing ownership by 100% to 0 units

    4 - Cellular Biomedicine Group, Inc. (0001378624) (Issuer)

    2/19/21 3:12:58 PM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CBMG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cellular Biomedicine Group, Inc. Announces Completion of Merger

    ROCKVILLE, Md. and SHANGHAI, Feb. 19, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") today announced the completion of the merger (the "Merger") of the Company with CBMG Merger Sub Inc., a Delaware corporation ("Merger Sub") and a wholly-owned subsidiary of CBMG Holdings, an exempted company with limited liability incorporated under the laws of the Cayman Islands ("Parent"), pursuant to the previously announced Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 11, 2020, by and among the Company, Parent and Merger Sub. Under the terms of the Merger Agreement, which was approved by the Company's stockholders at its special

    2/19/21 2:55:00 PM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Leading Proxy Advisory Firms Glass Lewis and ISS Recommend Cellular Biomedicine Group Stockholders Vote FOR Proposed Merger

    ROCKVILLE, Md. and SHANGHAI, Jan. 28, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("Company," "CBMG," "we" or "our"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced today that leading proxy advisory firms Glass, Lewis & Co. and Institutional Shareholder Services Inc. have both recommended that the Company's stockholders vote FOR the proposal to adopt the definitive merger agreement that provides for the acquisition of CBMG for $19.75 in cash per share of common stock in a going private transaction (the "merger proposal").  The Company will hold a special meeting o

    1/28/21 4:30:00 PM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cellular Biomedicine Group Announces Data to be Presented at 2020 ASH Annual Meeting

    GAITHERSBURG, Md. and SHANGHAI, Dec. 4, 2020 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced today that three abstracts relating to its immuno-oncology drug development have been accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition to be held as a virtual event on December 5-8, 2020. C-CAR088Abstract Title: An Anti-BCMA CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple MyelomaProgram: Oral and

    12/4/20 7:35:00 AM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CBMG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed

    SC 13D/A - Cellular Biomedicine Group, Inc. (0001378624) (Subject)

    2/19/21 7:50:47 PM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed

    SC 13D/A - Cellular Biomedicine Group, Inc. (0001378624) (Subject)

    2/19/21 3:44:36 PM ET
    $CBMG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care